NSCLC (following checkpoint inhibitors; combo with docetaxel) | XPORT-NSCLC-039
Title: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Please visit clinicaltrials.gov for more information about this study
This trial is for selinexor.
|Early Stage||Mid Stage||Late Stage||Commercial|